Navigation Links
Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System
Date:2/11/2011

MAHWAH, N.J., Feb. 11, 2011 /PRNewswire/ -- Stryker Corporation's (NYSE: SYK) Orthopaedics Division today announced U.S. Food and Drug Administration 510(k) clearance for its MDM X3 Modular Dual Mobility Mobile Bearing Hip System.  MDM X3 is an addition to the company's portfolio of next-generation technologies designed to minimize the risks traditionally associated with hip replacement surgery and address a broader patient population, including both primary and revision total hip arthroplasty candidates.

FDA 510(k) clearance for the MDM X3 Mobile Bearing Hip System follows the significant commercial success of the company's innovative ADM X3 Mobile Bearing Hip System which launched one year ago and contributed to Stryker's strong performance in the hip reconstruction market in 2010.

MDM X3 is a third-generation dual mobility device that allows surgeons to offer the benefits associated with Stryker's dual mobility technology to a broader patient population, including those who may benefit from advanced fixation.   Like Stryker Orthopaedics' ADM X3, MDM X3 is designed to enhance stability and jump distance, which may increase range of motion in specific patients.(1)

"MDM X3 builds on the significant success we've achieved with our Mobile Bearing Hip portfolio and provides surgeons with the versatility to bring the benefits of dual mobility constructs to a greater range of patients," said Bill Huffnagle, Vice President and General Manager, Hip Reconstruction, Stryker Orthopaedics.  "At Stryker Orthopaedics, we're continually focused on providing our surgeon customers with innovative designs and technologies to address the wide breadth of reconstructive challenges they face clinically.  The launch of MDM X3 reflects our commitment to improving patient outcomes through enhanced technologies."

ADM X3 Mobile Bearing Hip System is Stryker's fl
'/>"/>

SOURCE Stryker Orthopaedics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Stryker Declares a $0.18 Per Share Quarterly Dividend
2. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
3. Stryker Reports 9% Sales Growth, 13% Adjusted Net Earnings Growth for Quarter Ended December 31, 2010
4. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
5. TriMed, Inc. Announces Licensing Agreement with Stryker
6. Stryker Increases Expected 2010 Results and Provides 2011 Outlook
7. Stryker Completes Acquisition of the Neurovascular Division of Boston Scientific
8. Stryker to Present at Investor Conferences
9. Stryker Announces Election of New Director
10. Stryker Announces Additional $500 Million Share Repurchase Program and Declares a 20% Increase in Quarterly Dividend
11. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014 Somewhere between dropping five pounds ... forgotten. But Audicus , a next-generation hearing aids ... new year. Hearing loss is the third ... though it is often unaddressed. Forty-eight million Americans have ... hearing aid, mainly due to price. Hearing aids traditionally ...
(Date:12/19/2014)... 2014  Sage Analytics ( www.sageanalytics.com ), the ... the testing of marijuana potency and moisture content, ... Profiler, the industry,s first product suite capable of ... portable unit. Designed from the ground ... cannabis industry, the Luminary™ Profiler utilizes specially purposed ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Disease Market to 2017 - Patent ... as Aricept, Namenda, Avonex, Rebif and ...
... Leading events organiser UBM Live , a division ... a new event, CPhI South East Asia to cater to ... 10 to 12 May at the Jakarta International Expo in ... pharmaceutical events is being introduced to offer a meeting place ...
Cached Medicine Technology:Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15CPhI Global Portfolio Expands into South East Asia 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Coral Gables is ... service , Lice Troopers, with its new clinic location set ... Florida, takes the hassle out of dealing with this common ... one of their two salon clinic locations in South Florida, ... location. , The decision to expand developed naturally out of ...
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... 03, 2007 - Gastroesophageal reflux disease (GERD), often known ... been associated with cancers, asthma, recurrent aspiration and pulmonary ... of Gastroenterology examines whether GERD sufferers may have shorter ... on over 50,000 person-years of data, the study provides ...
... CAMBRIDGE, Mass., Jan. 3, 2008 -- Psychologists at Harvard ... perception that, they argue, can resolve the century-old debate ... not only illustrates a new method for studying such ... against the existence of extrasensory perception, or ESP. , ...
... 23 million Americans age 12 or older need treatment for ... than 10 percent actually receive it. Worse, among those ... treatments that are known to work. , We have treatments ... Paul Roman, University of Georgia Distinguished Research Professor of Sociology ...
... VICTORIA, Jan. 3 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... completion of the,plan of arrangement with Galenica Group ... Canadian subsidiary, acquired all,outstanding shares of Aspreva for ... completion of the plan of arrangement, Aspreva will ...
... Jan. 3 DaVita Inc. (NYSE:,DVA) announced today that ... January 7-11, 2008 at the Westin St. Francis Hotel ... will be presenting on,January 8, at 9:00 a.m. Pacific ... presentation will also be broadcast live and by replay. ...
... The Jeffrey Modell Foundation drives initiative for SCID screening, ... became the first,state in the nation to screen all ... "Bubble Boy Disease," SCID is a,genetic disorder that is ... referred for potentially life-saving treatment., The Wisconsin Department ...
Cached Medicine News:Health News:Researchers use neuroimaging to study ESP 2Health News:Researchers use neuroimaging to study ESP 3Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 2Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 3Health News:Aspreva's plan of arrangement with Galenica completed 2Health News:Aspreva's plan of arrangement with Galenica completed 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 2Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 4Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: